{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:10:26Z","timestamp":1778044226592,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1C1B5076522"],"award-info":[{"award-number":["2017R1C1B5076522"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.expneurol.2025.115264","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:12:37Z","timestamp":1744657957000},"page":"115264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A model of L-DOPA-induced dyskinesia in parkinsonian mice produced by AAV vector-mediated overexpression of \u03b1-synuclein"],"prefix":"10.1016","volume":"389","author":[{"given":"Jin Yong","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil Hyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2025.115264_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0006-8993(90)91318-B","article-title":"Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats","volume":"525","author":"Abercrombie","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2025.115264_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2025.115264_bb0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0020","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2025.115264_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0030","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson's disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115264_bb0035","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2025.115264_bb0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/14728222.2022.2153036","article-title":"Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing","volume":"26","author":"Cesaroni","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.expneurol.2025.115264_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mds.26144","article-title":"Serotonergic markers in Parkinson\u2019s disease and levodopa-induced dyskinesias","volume":"30","author":"Cheshire","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115264_bb0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","article-title":"Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease","volume":"235","author":"Decressac","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0060","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.nbd.2011.12.013","article-title":"Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons","volume":"45","author":"Decressac","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2025.115264_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3","article-title":"Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model","volume":"15","author":"Di Monte","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115264_bb0070","series-title":"Central Nervous System Disease: Innovative Animal Models from Lab to Clinic","author":"Emerich","year":"2000"},{"key":"10.1016\/j.expneurol.2025.115264_bb0075","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Franklin","year":"2008"},{"key":"10.1016\/j.expneurol.2025.115264_bb0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s004150050530","article-title":"Risk factors for levodopa-induced dyskinesias in Parkinson's disease","volume":"246","author":"Grandas","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0085","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuroscience.2015.04.021","article-title":"Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"298","author":"Keber","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2025.115264_bb0095","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","article-title":"Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatla system","volume":"22","author":"Kirik","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2025.115264_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017698","article-title":"Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein","volume":"6","author":"Koprich","year":"2011","journal-title":"PLoS One"},{"issue":"Pt 7","key":"10.1016\/j.expneurol.2025.115264_bb0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2025.115264_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","article-title":"Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease","volume":"85","author":"Lee","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2025.115264_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2012.05.022","article-title":"Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?","volume":"237","author":"Lindgren","year":"2012","journal-title":"Exp. Neurol."},{"issue":"338","key":"10.1016\/j.expneurol.2025.115264_bb0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"1979","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2025.115264_bb0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2025.115264_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2025.115264_bb0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-8-44","article-title":"rAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration","volume":"8","author":"Oliveras-Salva","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.expneurol.2025.115264_bb0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115264_bb0145","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00702-018-1874-4","article-title":"Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function","volume":"125","author":"Pisanu","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.expneurol.2025.115264_bb0150","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2025.115264_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.107.126219","article-title":"Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"323","author":"Putterman","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2025.115264_bb0160","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2025.115264_bb0165","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2025.115264_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0091-3057(89)90372-9","article-title":"Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage","volume":"34","author":"Schneider","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2025.115264_bb0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbr.2011.09.025","article-title":"Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia","volume":"226","author":"Smith","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2025.115264_bb0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1471-4159.2009.05904.x","article-title":"Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study","volume":"109","author":"Sossi","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2025.115264_bb0185","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2025.115264_bb0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.expneurol.2025.115264_bb0200","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","article-title":"alpha-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice","volume":"14","author":"Uemura","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2025.115264_bb0205","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.neurobiolaging.2014.11.015","article-title":"Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2025.115264_bb0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488625001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488625001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:10:50Z","timestamp":1778040650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488625001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"alternative-id":["S0014488625001281"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2025.115264","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model of L-DOPA-induced dyskinesia in parkinsonian mice produced by AAV vector-mediated overexpression of \u03b1-synuclein","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2025.115264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115264"}}